OCT Scanner Approved for use in Australia

Michelson Diagnostics  has received regulatory approval by the Therapeutics Goods Administration (TGA) in Australia to start selling its leading VivoSight OCT Scanner.

Australia has the highest incidence of skin cancer in the world and the number of people needing treatment continues to grow. The Australian Institute of Health and Welfare and Cancer Australia estimates there were 430,000 new cases of Non-Melanoma Skin Cancer diagnosed in 2008. This is approximately four-fold higher than the number of new cases diagnosed in the UK.

In a recent position statement, the Australasian College of Dermatology described the situation as “Australia’s skin cancer epidemic” calling for “Innovation with regards to new treatments, new methods of treatment delivery and earlier diagnosis is also required.”

The company expects that the adoption of the VivoSight OCT Scanner will help advance the diagnosis and treatment of Non Melanoma Skin Cancer and reduce the cost of care, which currently runs to many hundreds of millions of A$ per year.

Jon Holmes, CEO of Michelson Diagnostics commented “We have established VivoSight as the OCT imaging technology of choice amongst German Dermatologists, where we have systems placed in both large hospitals and private clinics. Using the knowledge we have gained from building our Germany business we are looking forward to a successful launch of the VivoSight OCT scanner in Australia."